Search Index

Elements, compounds, and mixtures make up the building blocks of materials that shape our world. Read on to uncover the latest contributions in chemistry, such as advances in mass spectrometry and quantum chemistry. Chemistry Articles Elements, compounds, and mixtures make up the building blocks of materials that shape our world. Read on to uncover the latest contributions in chemistry, such as advances in mass spectrometry and quantum chemistry. You may also like: Medicine , Pharmacology Advances in mass spectrometry Analytical chemistry Bioorthogonal chemistry Chemical reactions with high yields Polypharmacy Multiple medications Plastics and their environmental impact The same property that makes plastics so strong endangers the environment Quantum chemistry A relatively new field of chemistry Nanomedicine and targeted drug delivery An overview as to why nanoparticles are suitable for drug delivery Nanogels Smarter drug delivery Previous

Getting treatment can prevent things from getting worse Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Depression in Children 10/07/25, 10:17 Last updated: Published: 17/06/23, 12:46 Getting treatment can prevent things from getting worse It's normal for kids to feel sad, act grouchy, or be in a bad mood at times. But when a sad or bad mood lasts for weeks or longer, and when there are other changes in a child's behavior, it might be depression. Therapy can help children who are going through sadness or depression. And there are things parents can do, too. Getting the right care can prevent things from getting worse and help a child feel better. Symptoms of depression Sad or bad mood. A child may seem sad, lonely, unhappy, or grouchy. It can last weeks or months. A child may cry more easily. They may have more tantrums than before. Being self-critical. Kids going through depression may complain a lot. They may say self-critical things like, "I can't do anything right." "I don't have any friends." "I can't do this." "It's too hard for me." Lack of energy and effort. Depression can drain a child's energy. They might put less effort into school than before. Even doing little tasks can feel like too much effort. Kids may seem tired, give up easily, or not try. Not enjoying things. Kids don't have as much fun with friends or enjoy playing like before. They may not feel like doing things they used to enjoy. Sleep and eating changes. Kids may not sleep well or seem tired even if they get enough sleep. Some may not feel like eating. Others may overeat. Aches and pains. Some children may have stomach aches or other pains. Some miss school days because of not feeling well, even though they aren't sick. Causes of depression Some common reasons include: - life events like someone dying - moving schools or other big changes - physical health problems - experiencing physical, sexual or psychological abuse or neglect - witnessing violence or a traumatic event - if you have an unstable family environment Intervention Three of the more common methods used in depression treatment include: - cognitive behavioral therapy - interpersonal therapy - psychodynamic therapy Written by Chhaya Dhedi Related articles: Childhood stunting in developing nations / What does depression do to your brain? / Brain of a bully / Anxiety / Postpartum depression in adolescent mothers Project Gallery

Resources such as: other websites, textbooks, YouTube videos, and books to help! Aiding university students studying STEM subjects. Extra Resources A masterlist of other websites, textbooks, YouTube videos, and books to help with your studies, research and revision. You may also like: A-level resources, IB resources, Entrance exam preparation, FREE CV and PS checks!, STEM book reviews Representation in STEM Sisterhood in STEM GENERAL INFORMATION Referencing guide: Cite Them Right Cite this for me ZoteroBib (fast, free reference generator) Phrasebank to help with essays Free notes and textbooks: Studocu Grammar checker: Grammarly (available as a browser extension) Money financing for students: Save the Student Others: New Scientist (print and online magazine) BBC iPlayer science and nature documentaries WEBSITES TO AID STUDIES Science and maths: MME Revise Cognito Resources Access Tuition Maths Genie LibreTexts: biology , chemistry , physics , maths , engineering , and medicine HELP WITH RESEARCH Databases: - PubMed - MEDLINE (by National Library of Medicine) - ScienceDirect - Web of Science - Literature search: Google Scholar - Participate in actual research: Zooniverse - citizen science - Top multi-disciplinary journal in the field: Nature PHARMACOLOGY AND RELATED Reference sites: - Pharmgkb - Drug Bank - Check which drugs are in trial Textbooks: - Katzung's Basic & Clinical Pharmacology, 16th edition by Todd Vanderah, PhD - The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing by Andrew Hitchings, Daniel Burrage, Dagan Lonsdale and Emma Baker BIOLOGICAL SCIENCES TEXTBOOKS Biology: - Campbell & Reece - Molecular biology and genetics: Molecular Biology of the Cell. 4th edition - Molecular Cell Biology by Lodish et al - Anatomy and physiology: Marieb - Principles of Animal Physiology by Moyes and Schulte - Animal Physiology by Hill, Wyse, and Anderson - Developmental Biology by Barresi and Gilbert - Cancer: The Biology of Cancer by Robert A. Weinberg Biochemistry: - Medical Biochemistry b y N. Mallikarjuna Rao Neuroscience: - Purves et. al - Kandel Immunology: - Immunobiology, 5th edition The Immune System in Health and Disease Genetics: - Emery's Elements of Medical Genetics and Genomics by Turnpenny & Ellard - Lewin’s Genes by Krebs, Goldstein, and Kilpatrick - Human Molecular Genetics by Strachan and Read CHEMISTRY TEXTBOOKS Physical chemistry: - Atkins Physical Chemistry (latest edition) - Solid State Chemistry (Fourth Edition) by Lesley Smart and Elaine Moore Organic chemistry: - Jonathan Clayden Organic Chemistry (latest edition) Inorganic chemistry: - Atkins Physical Chemistry (latest edition) - Housecroft Inorganic Chemistry (latest edition) - Electronic Structure (Basic Theory and Practical Methods) by Richard M. Martin - Two-minute Neuroscience - Amoeba Sisters (biology related) - Khan Academy (all STEM based) - TEDx Talk - Royal Society (range of science videos) - NumberPhile - patrickJMT (maths) - Tyler DeWitt (general chemistry) - Crash Course - Stanford Medicine (wellness) PHYSICS Resources: - Astronomy Picture of the Day - NASA STEM activities Textbooks: - University Physics by Young and Freedman - Introduction to Electrodynamics by Griffiths - Introduction to Elementary Particles by Griffiths - Introduction to Quantum Mechanics by Griffiths - Modern Quantum Mechanics (Third Edition) by J. J. Sakurai and Jim Napolitano - Introductory Statistical Mechanics by Bowley & Sanchez - Statistical Mechanics: A Survival Guide by Glazer & Wark - Electricity and Magnetism by Morin and Purcell - Concepts in Thermal Physics by Blundell and Blundell - Introduction to Solid State Physics by Mittel & McEuen - Solid State Physics by Ashcroft and Mermin - Space, Time, and Geometry by Sean M. - Density Functional Theory by David S. Sholl and Janice A. Steckel - The Physics of Semiconductors: An Introduction Including Nanophysics and Applications by Marius Grundmann - Quantam Field Theory for the Gifted Amateur by Tom Lancaster & Stephen J. Blundell - Condensed Matter Field Theory (Second Edition) by Alexander Altland and Ben Simons - Condensed Matter Physics by Michael P. Marder MATHS Textbooks: - Mathematical Methods for Physicists and Engineers by Riley Benson and Hobson - Mathematics for Natural Scientists 1 and 2 by Lev Kantorovich - Advanced Engineering Mathematics by Kreyszig - Thomas's Calculus by George B. Thomas - Mathematical Methods for Science students by G Stephenson - Contemporary Abstract Algebra by Joseph A. Gallian Read this article on how to excel in maths COMPUTER SCIENCE AND RELATED Resources: - Codeacademy - W3Schools ( has tutorials for HTML/ CSS/ Javascript, Python, Java, and many other languages) - Adacomputerscience - TeachComputing - Codewars (practise coding with your friends) - freeCodeCamp ENGINEERING Resources: - eFunda- formulae - Engineering statistics handbook - The Engineering Toolbox - free tools, calculators, and more - Engineers Edge - Online Ethics - ethics in engineering and science PSYCHOLOGY Resources: - QMUL resource guides - Psychology Today - Royal Holloway activities and research - Verywell Mind INFORMATIVE YOUTUBE CHANNELS

Comparative oncology Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link What can our canine friends tell us about cancer? 14/07/25, 15:12 Last updated: Published: 02/07/24, 10:04 Comparative oncology Comparative oncology is a field of study within cancer that has been adopted to study cancer and develop new therapies. It involves studying cancer in animals to uncover similarities between human and animal cancers. By combining scientific findings across a range of species, including companion animals such as dogs and horses or non-human primates such as monkeys, comparative oncology will advance cancer research and help develop effective novel therapies. This approach not only explores cancers in both animals and humans but also aims to bridge the gap between human and veterinary medicine. By examining similarities and differences in cancer biology, progression and treatment responses across species, comparative oncology provides valuable insights that can benefit both fields. Understanding how cancer behaves in animals can offer new perspectives and potential therapies for human patients. Conversely, while findings in human oncology can inform veterinary medicine, leading to improved diagnostics and treatments for animals. ( Figure 1 summarises the aims of comparative oncology). This article aims to explore this field of oncology further by discussing what it entails, the methodologies utilised, some recent advancements, and finally, things to look out for in the future. Comparative oncology has been developed and expanded into two areas of study. This includes spontaneous oncology and experimental oncology. Spontaneous oncology focuses on naturally occurring tumours in animals by investigating aspects of carcinogenesis, epidemiology, diagnosis, and treatment. It provides unique insights by drawing comparisons with human oncology research. These results can then be extrapolated to human oncology to gain a better understanding of cancer. This is because the similarities and differences observed in naturally occurring tumours across species provide valuable insights into underlying mechanisms within tumours and treatment responses. Experimental oncology serves as a distinct discipline where there are specialisations such as studying viral, chemical, and radiation oncogenesis alongside studying environmental factors such as pollution residues and food additives. This area involves studying both spontaneous tumours in animals and lab settings, where controlled conditions are used to explore different parts of cancer biology and treatment strategies. Additionally, the primary methodology utilised in comparative oncology involves studying spontaneous tumours in animals. Unlike artificially induced tumours in lab animals, these spontaneous tumours in pets closely mimic the complexity and heterogeneity of human cancers. For example, canines will live in similar living environments and experience similar external stimuli to their owner, such as pollution. The nature of these external stimuli means that they develop cancer in similar ways caused by epigenetic alterations, metabolic, and immune changes. (Figure 2 illustrates this process). Furthermore, comparative oncology uses advanced imaging techniques, genetic analysis, and immunological studies to predict pathways that may be shared among animals and humans which, could drive cancer development. Overall, these methods will allow the identification of promising therapies which directly target cancer and expand on current treatment choices such as chemotherapy and immunotherapy. One of the recent advancements in comparative oncology relates to osteosarcomas. This refers to cancer cells which begin to grow in the bones. For this specific form of cancer, molecular signatures were identified to predict clinical outcomes for both humans and canines, which can help improve treatment outcomes. Led by Amy K. LeBlanc, scientists have identified gene activity patterns in osteosarcoma tumours in nearly 200 dogs, revealing distinct groups with varying prognoses. These findings help us understand the biology behind osteosarcomas further and can potentially help us develop targeted therapies that take advantage of the immune system to treat the disease in both species. This potentially includes a range of therapies including PD-L1 inhibitors and cancer vaccines targeting the immune system. Moreover, breakthroughs in immunotherapies such as checkpoint inhibitors and CAR-T cell therapy are effective in treating haematological malignancies in both humans and canines. Furthermore, studies in canine melanoma reveal similar gene expression changes to human melanoma, such as in the PI3K/AKT/mTOR and MAPK pathways, even when the driver mutations are different. (Figure 3 shows how the pathway contributes to cancer). Useful data was provided in trials using companion animals with spontaneous tumours, providing an insight into safety, dosage, and efficacy, which have paved the way to develop treatments for both species. To conclude, it is clear with comparative oncology, researchers will be able to identify new molecular targets, assess novel drugs, and identify patient populations which will benefit the most from these therapies. It holds great promise in helping streamline cancer diagnosis further and even plays a role in preventing cancer. While the field shows great potential, more studies still need to be conducted to understand the similarities and differences in cancers between animals and humans. Additionally, more collaboration is needed amongst oncologists, veterinarians, and researchers across these disciplines to harness collective expertise to address questions relating to cancer diagnosis, treatment, and prevention. Ultimately, this field will help us identify new avenues of treating and diagnosing cancer whilst improving healthcare outcomes for humans and animals alike. Written by Harene Elayathamby Related articles: Why blue whales don't get cancer / Rare zoonotic diseases REFERENCES Schiffman, J.D. and Breen, M. (2015) ‘Comparative oncology: What dogs and other species can teach us about humans with cancer’, Philosophical Transactions of the Royal Society B: Biological Sciences , 370(1673), p. 20140231. doi:10.1098/rstb.2014.0231. Oh, J.H. and Cho, J.-Y. (2023) ‘Comparative oncology: Overcoming human cancer through companion animal studies’, Experimental & Molecular Medicine , 55(4), pp. 725–734. doi:10.1038/s12276-023-00977-3. Al, B. and C., C. (2007) ‘Chapter 1 COMPARATIVE ONCOLOGY ’, in Comparative oncology . Bucharest (RO): The Publishing House of the Romanian Academy, p. 1. Vail, D.M., LeBlanc, A.K. and Jeraj, R. (2020) ‘Advanced cancer imaging applied in the comparative setting’, Frontiers in Oncology , 10. doi:10.3389/fonc.2020.00084. New findings highlight shared features of human and canine osteosarcoma (2023) Center for Cancer Research . Available at: https://ccr.cancer.gov/news/article/new-findings-highlight-shared-features-of-human-and-canine-osteosarcoma (Accessed: 02 March 2024). Mochel, J.P. et al. (2018) Car T-cell immunotherapy in human and veterinary oncology: Changing the odds against hematological malignancies [Preprint]. doi:10.20944/preprints201811.0525.v1. LeBlanc AK, Mazcko CN, Khanna C. (2016) ‘Defining the Value of a Comparative Approach to Cancer Drug Development’, Clinical cancer research : an official journal of the American Association for Cancer Research , 22(9). p. 2133-2138. doi: 10.1158/1078-0432.CCR-15-2347 FIGURE REFERENCES Boddy, A.M., Harrison, T.M. and Abegglen, L.M. (2020) ‘Comparative oncology: New insights into an ancient disease’, iScience , 23(8), p. 101373. doi:10.1016/j.isci.2020.101373. Oh, J.H. and Cho, J.-Y. (2023) ‘Comparative oncology: Overcoming human cancer through companion animal studies’, Experimental & Molecular Medicine , 55(4), pp. 725–734. doi:10.1038/s12276-023-00977-3. Rascio, F. et al. (2021) ‘The pathogenic role of PI3K/Akt pathway in cancer onset and drug resistance: An updated review’, Cancers , 13(16), p. 3949. doi:10.3390/cancers13163949. Project Gallery

From the eyes of a chemist Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Polypharmacy: the complex landscape of multiple medications 10/07/25, 10:30 Last updated: Published: 21/09/24, 15:48 From the eyes of a chemist The concurrent use of many medications by a patient, known as polypharmacy, poses a complex challenge to modern healthcare, especially for the elderly and those with chronic diseases. Polypharmacy raises the risk of adverse drug responses, drug interactions, and medication non-adherence, even though it is essential for managing complicated health concerns. To maximise patient outcomes and guarantee safe treatment regimens, it is crucial to recognise the chemical interactions and effects of different medications. The chemistry behind polypharmacy Polypharmacy stems from the intricate interactions between several chemicals in the human body. Every drug has unique chemical components intended to interact with biological targets in order to provide therapeutic benefits. Nevertheless, when several medications are taken at once, their combinations may have unexpected effects. Understanding polypharmacy requires a thorough understanding of pharmacokinetics—the way the body absorbs, distributes, metabolises, and excretes medications—and pharmacodynamics—the effects of pharmaceuticals on the body. For example, some pharmaceuticals may cause or inhibit the enzymes that metabolise other drugs, changing the levels of the drug and possibly increasing its toxicity or decreasing its effectiveness. Analytical methods in polypharmacy management Chemistry offers a number of analytical and instrumental techniques for efficient polypharmacy management. Drug levels in the blood are tracked using methods like mass spectrometry (MS) and high-performance liquid chromatography (HPLC) to make sure they stay within therapeutic ranges. These techniques support dose modifications by identifying possible medication interactions. Furthermore, it is impossible to exaggerate the importance of chemistry in the creation of drug interaction databases and predictive modelling instruments. By helping medical professionals foresee and minimise harmful medication interactions, these materials help to ensure patient safety. The role of healthcare professionals To successfully manage the complexity of polypharmacy, healthcare professionals—including physicians, chemists, and nurses—need to have a solid understanding of chemistry. Their expertise is essential for assessing each drug's requirement, taking possible interactions into account, and coming up with methods to make drug regimens easier to follow. Managing polypharmacy is especially important for chemists. They assess patients' prescriptions, look for any interactions, and suggest changes or substitutes using their knowledge of medicinal chemistry. Pharmacists who participate in collaborative care can greatly lower the hazards related to polypharmacy. Innovations in medication management Chemistry-driven advances in medical technology are improving polypharmacy management. Real-time alerts regarding potential drug interactions can be provided to prescribers through computerised physician order entry (CPOE) systems that are coupled with clinical decision support systems (CDSS). Optimising polypharmacy may also be possible with the emergence of personalised medicine, which adjusts drug regimens according to a patient's genetic profile. Conclusion Polypharmacy remains a significant challenge in healthcare, demanding a comprehensive understanding of chemistry and pharmacology to manage effectively. Healthcare practitioners can minimise the hazards associated with several medications and provide safer and enhanced patient care by utilising modern analytical methods, prediction technologies, and multidisciplinary teamwork. Written by Laura K Project Gallery

Tackling stereotypes and equal access Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Why representation in STEM matters Last updated: 03/04/25, 10:38 Published: 13/03/25, 08:00 Tackling stereotypes and equal access In collaboration with Stemmettes for International Women's Month Representation in Science, Technology, Engineering, and Mathematics (STEM) and Science, Technology, Engineering, Art and Mathematics (STEAM), is crucial for everyone. Historically, STEM fields have been dominated by certain demographics that don’t show the true picture of our world. Maybe you grew up seeing no (or very few) women, people of colour, or other marginalised groups mentioned in your science curriculum. This needs to change because your voice, experiences and talents should be celebrated in any career you choose. Below, we’ll list some of the top reasons why representation is so important. Equal access Why does representation matter? Because it promotes equal access! Whether in an educational or career setting, seeing someone who looks like you do something you never thought possible can be life-changing. After all, you can’t be what you can’t see . Showing up in your role and sharing what you do or your STEM/STEAM interests show other people that these fields are accessible to everyone. Also, finding someone in a field you are (or would like to) get into is a great way to find a mentor, build a network, and boost your knowledge. Feeling excluded or discouraged is bound to happen at some point in your career, but anyone can succeed, no matter their background. Innovation When STEM fields are equally represented, better (and more innovative) ideas come to the table. Everything you’ve experienced can be useful in developing solutions to STEM and STEAM problems, no matter your level of education or upbringing. A lot of STEM doesn’t rely so much on your qualifications, but instead on your problem-solving, creativity, and innovation skills. For example, if you’re part of a culture that nobody else in your team has experienced, or you’ve experienced a disability and made adaptations for yourself, you bring a unique set of ideas to the table that can help solve many different problems. Inclusion There are many examples of when certain demographics haven’t been included in STEM decision-making processes. For example, many face recognition apps have failed to recognise the faces of people of colour, and period trackers have been made with misinformation about cycle lengths. If more diversity were seen throughout the process of creating a STEM product or service, we would see a lot fewer issues and a lot better products! Now, more than ever, your voice is important in STEM because science and technology are shaping the future at a fast rate. With the boom in artificial intelligence (AI) technology and its impact on almost every industry, we can’t afford to have models being trained from an unrepresentative data set. Look at people like Katherine Johnson, who despite facing setbacks as an African American at the time, was a pivotal part of sending astronauts aboard Apollo 11 into space. Or, more recently, Dr Ronx, who is paving the way as a trans-non-binary emergency medicine doctor. Tackling stereotypes Showing up in STEM & STEAM fields is a great way to tackle stereotypes. So many underrepresented groups are usually stereotyped into different career paths that are based on old, outdated notions about what certain people should do. By showing up and talking about what you love, you show that you’re not less capable than anyone else. Shout about your achievements, no matter how big or small, no matter where you are on your career journey so that we can encourage a new idea of what STEM looks like. Conclusion If this article hasn’t already given you the confidence to explore STEM and STEAM fields and all they have to offer, there are so many other reasons why you’re important to these fields and capable of achieving your dreams. Representation from you and others helps us create a more equitable, innovative, and inclusive future. It matters because the progress of science and society depends on the contributions of all, not a select few. Written by Angel Pooler -- Scientia News wholeheartedly thanks Stemmettes for this pertinent piece on the importance of representation in STEM. We hope you enjoyed reading this International Women's Month Special piece! Check out their website , and Zine / Futures youth board (The Stemette Futures Youth Board is made up of volunteers aged 15-25 from the UK and Ireland who will ensure the voices of girls, young women and non-binary young people are heard. They will work alongside the Stemette Futures charity board to guide and lead the mission to inspire more girls, young women and non-binary young people in to STEAM). -- Related articles: Sisterhood in STEM / Women leading in biomedical engineering / African-American women in cancer research Project Gallery

...In the nerve fibre world Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Squids are size champions 11/07/25, 09:53 Last updated: Published: 29/06/23, 09:33 ...In the nerve fibre world A cephalopod adventure When you think of squids, you probably imagine them swimming through the ocean and using tentacles to catch their prey. Scientists might not! These slimy sea creatures have helped us to study and understand how our own nervous system works. That’s right, squids are more than just tasty seafood. Squids have a giant axon, which is a single nerve fiber that is much larger than the axons found in other animals, including humans. This giant axon can be up to one millimeter in diameter , which is big enough to be seen with the naked eye. If you’re thinking that 1 millimeter is still pretty small, consider that human axons are measured in micrometers (µm) , so the squid’s giant axons are almost one thousand times larger in diameter than ours . In case you’re wondering what an axon is, it’s the long projection of a neuron that conducts electrical impulses away from the cell body. The electrical impulses generated during an action potential travel down the axon and make their way to the synapse. So the axon is a vital component of the nervous system that helps facilitate communication between neurons and other cells. In 1963, the English scientists Hodgkin and Huxley were awarded the Nobel Prize for their groundbreaking experiments on squid giant axons. Through their work, they provided a detailed understanding of the electrical properties of axon membranes and the role of ion channels in generating and propagating nerve impulses. They also discovered that the giant axon is surrounded by a thick layer of insulation called myelin , which speeds up the transmission of nerve impulses. Their research has been fundamental to the development of modern neurophysiology. So, the next time you enjoy a plate of calamari, remember that the squid on your plate might have contributed to our understanding of the nervous system. Written by Viviana Greco Related article: Frog nerves Project Gallery

The concept of memory erasure is huge and complex Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Can you erase your memory? 09/07/25, 13:31 Last updated: Published: 23/11/23, 11:08 The concept of memory erasure is huge and complex What is memory? Our brain is a wiggly structure in our skull, made up of roughly 100 billion neurones. It is a wondrous organ, capable of processing 34 gigabytes of digital data per day, yet being able to retain information, and form memory – something that many would argue, defines who we are. So.. what is memory? And how does our brain form them? Loosely defined, memory is the capacity to store and retrieve information. There are three types of memory: short-term, working, and long-term memory (LTM). Today, we will be focusing on LTM. In order to form LTM, we need to learn and store memory. This follows the process of encoding, storage, retrieval, and consolidation. In order to understand the biochemical attributes of memory in our brain, a psychologist, Dr Lashley, conducted extensive experiments on rats to investigate if there were specific pathways in our brain that we could damage to prevent memory from being recalled. His results showed that despite large areas of the brain being removed, the rats were still able to perform simple tasks ( Figures 1-2 ). Lashley’s experiment transformed our understanding of memory, leading to the concept of “engrams”. Takamiya et al., 2020 defines “memory engrams” as traces of LTM consolidated in the brain by experience. According to Lashley, the engrams were not localised in specific pathways. Rather, they were distributed across the whole of the brain. Can memory be erased? The concept of memory erasure is huge and complex. In order to simplify this, let’s divide them into two categories: unintentional, and intentional. Let’s take amnesia for example. This is a form of unintentional memory ‘erasure’. There are two types of amnesia: retrograde amnesia, and anterograde amnesia. Retrograde amnesia is the loss of memory that was formed before acquiring amnesia. On the other hand, anterograde amnesia is the inability to make new memories since acquiring amnesia. Typically, a person with amnesia would exhibit both retrograde, and anterograde amnesia, but at different degrees of severity ( Figure 3 ). Can we ‘erase’ our memory intentionally? And how would this be of use to us? This is where things get really interesting. Currently, the possibility of intentional memory ‘erasure’ is being investigated in patients for the treatment of post-traumatic stress disorder (PTSD). In these clinical trials, patients with PTSD are given drugs that block these traumatic memories. For example, propranolol, an adrenergic beta receptor blocker impairs the acquisition, retrieval, and reconsolidation of this memory. Incredible, isn’t it? Although this is not the current standard treatment for PTSD, we can only imagine how relieving it would be for our fellow friends who suffer from PTSD if their traumatic memories could be ‘erased’. However, with every step ahead, we must always be extremely cautious. What if things go wrong? We are dealing with our brain, arguably one of the most important organs in our body after all. Regardless, the potential for memory ‘erasure’ in treating PTSD seems both promising and intriguing, and the complexities and ethical considerations surrounding such advancements underscore the need for careful and responsible exploration in the realm of neuroscience and medicine. Written by Joecelyn Kiran Tan Related articles: Synaptic plasticity / Boom, and you're back! (intrusive memories) / Sleep and memory loss Project Gallery

Exenatide as a potential drug Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A common diabetes drug treating Parkinson’s disease 08/07/25, 14:37 Last updated: Published: 24/01/24, 21:15 Exenatide as a potential drug A new investigational drug, originally developed for type 2 diabetes, is being readied for human clinical trials in search of the world's first treatment to impede Parkinson's disease progression. Parkinson's (PD) is the second most common neurodegenerative disorder. The connection between type 2 diabetes (T2DM) and PD was discovered in 1993, when PD patients with co-existing T2DM had worse motor symptoms and response to therapy. Dopaminergic neurons promote eating behaviour in hypoglycaemic states, mediated via insulin receptors in the substantia nigra, because dopaminergic neuronal loss affects glycaemic control. Thus, T2DM patients are more likely to acquire PD than people without diabetes. Excess glucose in the brain, as found in uncontrolled T2DM, may interact randomly with surrounding proteins and interfere with their function. These interactions also result in toxic end products promoting inflammation and α-synuclein clustering, both of which are PD characteristics. Over a 12-year period, retrospective data (N=8,190,323) showed that T2DM responders had considerably greater PD rates when compared to those without diabetes. The rise was significantly more pronounced among individuals with complex T2DM and those aged 25-44. Exenatide: Overview and Mechanism of Action Exenatide is a synthetic form of exendin-4, a naturally occurring protein identified in the saliva of the Gila monster (poisonous lizard endemic to the Southwest US) by Dr. Eng in the early 1990s. In humans, the chemical is produced after a meal to increase insulin production, decreasing blood sugar. GLP-1 degrades fast in humans, and its benefits are short-lived. However, investigations have shown effects of exendin-4 continue longer in people. This finally led to FDA clearance in 2005, when the product was sold as Byetta TM . Its current indications are for the treatment of balancing glucose levels in T2DM with or without additional oral hypoglycemic medications. This glycaemic control is an analogue of human GLP-1, used in T2DM treatment, either alone or in conjunction with other antidiabetic medications. Exendin-4's neuroprotective characteristics may aid in rescuing degenerating cells and neuron protection. Because T2DM and PD are linked, researchers want to explore its effectiveness as a PD therapy. Patients treated with exenatide for one year (in addition to standard medication) experienced less deterioration in motor symptoms when tested without medication compared to the control group. Research on Exenatide as a Potential Parkinson's Disease Therapy 21 patients with intermediate PD were assessed over a 14-month period, and their progress was compared to 24 other people with Parkinson's who served as controls. Exenatide was well accepted by participants, albeit some individuals complained about weight loss. Significantly, exenatide-treated participants improved their PD movement symptoms, while the control patients continued to deteriorate. The researchers investigate exenatide, a possible PD therapy, in an upcoming clinical study, lending support to the repurposing of diabetes drugs for Parkinson's patients. This research adds to the evidence for a phase 3 clinical trial of exenatide for PD patients. Data on 100,288 T2DM revealed that people using two types of diabetic medications, GLP-1 agonists and DPP4-inhibitors, were less likely to be diagnosed with Parkinson's up to 3.3 years follow-up. Those who used GLP-1 agonists were 60% less likely to acquire PD than those who did not. The results revealed that T2DM had a higher risk of Parkinson's than those without diabetes, although routinely given medicines, GLP-1 agonists, and DPP4-inhibitors seemed to reverse the association. Furthermore, a 2-year follow-up research indicated individuals previously exposed to exenatide displayed a substantial improvement in their motor characteristics 12 months after they ceased taking the medication. However, this experiment was an open-label research so the gains may be explained by a placebo effect. The research adds to the evidence that exenatide may assist to prevent or treat PD, perhaps by altering the course of the illness rather than just lowering symptoms. Other risk factors for PD should be considered by clinicians when prescribing T2DM drugs, although further study is required to clarify clinical significance. Findings from Clinical Trials and Studies Based on these findings, the UCL team broadened their investigation and conducted a more extensive, double-blind, placebo-controlled experiment. The findings establish the groundwork for a new generation of PD medicines, but they also confirm the repurposing of a commercially existing therapy for this illness. Patients were randomly randomised (1:1) to receive exenatide 2 mg or placebo subcutaneous injections once weekly in addition to their current medication for 48 weeks, followed by a 12-week washout period. Web-based randomisation was used, with a two-stratum block design depending on illness severity. Treatment allocation was concealed from both patients and investigators. The main outcome was the adjusted difference in the motor subscale of the Movement Disorders Society Unified Parkinson's Disease Rating Scale after 60 weeks in the realistically defined off-medication condition. Six major adverse events occurred in the exenatide group and two in the placebo group, but none were deemed to be connected to the research treatments in either group. It is unclear if exenatide alters the underlying illness mechanism or causes long-term clinical consequences. Implications and Future Directions Indeed, the UCL study showed that exenatide decreases deterioration compared to a placebo. However, participants reported no change in their quality of life. The study team would broaden their study to include a broader sample of people from several locations. Because PD proceeds slowly, longer-term trials might provide a better understanding of how exenatide works in these responders. Overall, findings suggest that gathering data on this class of medications should be the topic of additional inquiry to evaluate their potential. Exenatide is also being studied to see whether it might postpone the onset of levodopa-induced problems (e.g., dyskinesias). Furthermore, if exenatide works for Parkinson's, why not for other neurodegenerative illnesses (Alzheimer's, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis) or neurological diseases (including cerebrovascular disorders, traumatic brain injury...)? Exenatide has been FDA-approved for diabetes for many years and has a good track record, but it does have some adverse side effects in Parkinson's patients, namely gastrointestinal difficulties (nausea, constipation). Exenatide as a prospective PD therapy is an example of medication repurposing or repositioning, an essential method for bringing novel therapies to patients in a timely and cost-effectively. However, further research is required, so it will be many years before a new therapy is licenced and available. Drug repurposing, or using authorised medicines for one ailment to treat another, opens up new paths for Parkinson's therapeutic development. Conclusion Exenatide shows potential as a therapy for Parkinson's disease (PD). Studies have shown that exenatide may help improve motor symptoms and slow down the progression of PD. However, further research and clinical trials are needed to fully understand its effectiveness and long-term effects. The findings also suggest that repurposing existing medications, like exenatide, could provide new avenues for developing PD therapies. While exenatide shows promise, it will likely be many years before it is licensed and widely available as a PD treatment. PROJECT GALLERY IMAGES DESCRIPTION Figure 1- The use of GLP-1 is beyond diabetes treatment. Nineteen clinical studies found that GLP-1 agonists can improve motor scores in Parkinson's Disease, improve glucose metabolism in Alzheimer's, and improve quality of. They can also treat chemical dependency, improve lipotoxicity, and reduce insulin resistance. However, adverse effects are primarily gastrointestinal. Thus, GLP-1 analogues may be beneficial for other conditions beyond diabetes and obesity. Figure 2- Potent GLP-1 agonists suppress appetite through a variety of mechanisms, including delayed gastric emptying, increased glucose-dependent insulin secretion, decreased glucagon levels, and decreased food ingestion via central nervous system effects. Short-acting agents, including exenatide, primarily function by impeding gastric evacuation, thereby leading to a decrease in postprandial glucose levels. On the contrary, extended-release exenatide and other long-acting agonists (e.g., albiglutide, dulaglutide) exert a more pronounced impact on fasting glucose levels reduction via their mechanism of action involving the release of insulin and glucagon. The ineffectiveness of long-acting GLP-1 receptor agonists on gastric evacuation can be attributed to the development of tolerance to GLP-1 effects, which is regulated by parasympathetic tone alterations. Figure 3- Illustrated is the cross-communication with insulin receptor signalling pathways and downstream effectors . Biomarkers can be derived from the formation and origin of extracellular vesicles, which indicate the initial inward budding of the plasma membrane. An early endosome is formed when this membrane fuses; it subsequently accumulates cytoplasmic molecules. As a consequence, multivesicular bodies are generated, which subsequently fuse with the plasma membrane and discharge their constituents into the extracellular milieu. Akt denotes protein kinase B; Bcl-2 signifies extracellular signal-related kinase; Bcl-2 antagonist of death; Bcl-2 extra large; Bcl-XL signifies Bcl-2; Bim signifies Bcl-2-like protein 11; cAMP signifies cyclic adenosine monophosphate; CREB signifies cAMP response element-binding protein; Erk1/2 signifies extracellular signal-related kinase IDE, insulin-degrading enzyme; IL-1α, interleukin 1α; IRS-1, insulin receptor signalling substrate 1; MAPK, mitogen-associated protein kinase; mTOR, mechanistic target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; NF-kB, nuclear factor–κB; PI3-K, phosphoinositide 3-kinase; PKA, protein kinase; FoxO1/O3, forkhead box O1/O3, forkhead box O1/O3; GRB2, growth factor receptor-bound protein 2; GSK-3β, Written by Sara Maria Majernikova Related articles: Pre-diabetes / Will diabetes mellitus become an epidemic? / Parkinson's risk / Markers for Parkinsonism Project Gallery

Also known as Major Depressive Disorder (MDD) Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link What does depression do to your brain? 14/07/25, 15:12 Last updated: Published: 10/10/24, 11:19 Also known as Major Depressive Disorder (MDD) This is Article 1 in a series on psychiatric disorders and the brain. Next article: Inside out: the chemistry of depression. -- I affect 3.8% of the population wide, With 280 million voices struggling inside. In women, my reach is 6%, And 5.7% of those over 60 feel me. Among new mothers, I reach 10%, With over 700,000 lost to my torment each year. What am I? Depression. The most prevalent psychiatric disorder that costs both money and lives. -- Also known as Major Depressive Disorder (MDD), depression is a heterogenous disease, which means the manifestation of the disorder is influenced by multiple genes. It is commonly known that consistent low mood, loss of interest in hobbies you used to enjoy, lethargy, feeling of hopelessness etc. are physical symptoms of depression. However, have you ever wondered what happens in the brain in a depression sufferer, from the neuroscience aspect? Structurally, research into the neuroscience of depression reveals significant structural abnormalities in the brains of affected individuals. Studies using structural magnetic resonance imaging (MRI) have shown that those with MDD show reductions in gray matter volume in regions responsible for emotion regulation. The limbic system of the brain is responsible for producing and regulating emotions. In depressed individuals, the hippocampus—a key component of the limbic system—shows reduced gray matter volume, which is linked to abnormalities in the associated white matter tracts. White matter consists of myelinated axons that facilitate communication between different brain regions, while grey matter contains the neuronal cell bodies responsible for processing information. The presence of abnormalities in white matter suggests a disconnection between regions within the limbic system, potentially impairing their ability to communicate effectively. This disconnection may contribute to the emotional dysregulation observed in depression, highlighting the intricate relationship between grey and white matter in the pathology of this disorder. Depression is a complex disorder that not only affects mood but changes the structure and function of the brain. By understanding the neurobiological changes—including reductions in grey matter and white matter disconnections—we can better grasp the pathogenesis of this condition. Continued research in the neuroscience behind depression is essential for developing more effective treatments. There is still much more to explore and understand in depression research; with each new discovery, we realise how much more there is to learn. Written by Chloe Kam Related article: Depression in children Project Gallery